Statement by Michael A. Carrier to Senate Judiciary Committee on 'Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition'

Senate Judiciary Committee hearing May 7, 2019

Rutgers Law School Research Paper

2 Pages Posted: 6 Sep 2019

Date Written: May 7, 2019

Abstract

In my testimony to the Senate Judiciary Committee, I explained the benefits of legislation addressing anticompetitive conduct that brand-name drug companies have employed: sample denials, pay-for-delay settlements, citizen petitions, product hopping, and patent thickets. By increasing generic competition, this legislation would make patients’ lives better without affecting innovation.

Keywords: pharmaceuticals, drugs, antitrust, sample denials, pay-for-delay settlements, citizen petitions, product hopping, patent thickets

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Statement by Michael A. Carrier to Senate Judiciary Committee on 'Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition' (May 7, 2019). Senate Judiciary Committee hearing May 7, 2019, Rutgers Law School Research Paper , Available at SSRN: https://ssrn.com/abstract=3442650

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
41
Abstract Views
321
PlumX Metrics